Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we better understand mpox in young people?

NCT ID NCT05947786

Knowledge-focused Sponsor: PENTA Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study gathers information from routine medical care on infants, children, and adolescents under 18 with confirmed mpox infection. Researchers aim to collect standardized data on symptoms, treatments, and outcomes to better understand how the disease affects young people. The study may expand to include more detailed data collection and sub-studies if needed. It also tracks infants born to mothers infected with mpox during pregnancy to see if the virus passes to the baby.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide a clearer picture of how mpox affects young people, guiding better treatments and public health responses.
What could go wrong
As an observational study, it does not test a new treatment, so it cannot directly improve outcomes. Data collection depends on routine care, which may vary across sites.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,108 people

The number who actually took part.

Started

Mar 2023

Finished

Oct 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Infants, children and adolescents with laboratory-confirmed mpox infection, including adolescent girls who acquired mpox in pregnancy, and infants who acquired mpox through vertical transmission. Phase 1 participants' consent may not be necessary as data collected is anonymous, phase 2 observational study participation would require participants'/ parent or legal representative consent as data collected is pseudonymised.

Ages

0 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * all infants, children and adolescents aged \<18 years at the time of mpox diagnosis, with laboratory-confirmed mpox infection, as per national guidelines; * mothers of eligible infants who are diagnosed with mpox at 28days or less are included in the study to collect maternal data on pregnancy and delivery Exclusion Criteria: * adolescents aged over 18 years old at mpox diagnosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monkey pox are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Monkey pox Monkeypox

Contacts and locations

Locations

  • Hospital La Paz

    Madrid, Spain

  • Institute of Human Virology Nigeria

    Abuja, Nigeria

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

    Mexico City, Mexico

  • Noguchi Memorial Institute for Medical Research

    Accra, Ghana

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • University of Kinshasa

    Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.